Overview of the rationale and the options of stem cells therapies in MS and review of the existing clinical experience
ECTRIMS Online Library. Karussis D. Oct 12, 2018; 232034; 281
Dimitrios Karussis
Dimitrios Karussis
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Discussion Forum (0)
Rate & Comment (0)

Abstract: 281

Type: Educational Session

Abstract Category: N/A

Due to the limited capacity of CNS for regeneration, more effective treatment
of chronic degenerative and inflammatory neurological conditions, such as MS may, theoretically at least, involve the use of stem cells which seem to carry the potential for regeneration and neuroprotection. Small number of stem cells are found in the adult brain in very specific regions, but this intrinsic stem cell repertoire is rather small and limited in its function by several factors (inhibiting factors, limited migration ability). It therefore only partially contributes to the repair of damaged tissues.
Transplantation of stem cells has long been suggested as a possible logical approach for repair or neuroprotection of the damaged nervous system. Embryonic cells carrying the pluripotent and self-renewal properties represent the prototype of stem cells, but there are additional somatic stem cells that may be harvested and expanded from various tissues during adult life, such as the mesenchymal stem cells (MSC), which offer several practical advantages for the clinical application. MSC can be obtained from every adult and there are effective culture protocols for their expansion to large numbers for clinical uses. They seem to carry less risks for malignancies and there are initial indications of their safety and clinical efficacy in pilot trials in patients with various neurological conditions. In my talk I will summarize the clinical experience (from our group and others) with stem cells, especially MSC, in MS and other neuroinflammatory or neurodegenerative diseases, describing the rationale, the hardles, the risks and the promise of such experimental therapeutic approaches.
Disclosure: Karussis Dimitrios: Nothing to disclose

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings